Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models

By AnnaBershteyn  Dr. Lise Jamieson  Hae-YoungKim  Ingrida Platais  Masabho PMilali  Edinah Mudimu  Debraten Brink  RowanMartin-Hughes  Sherrie L Kelly  et al  |  | 

In this so-called treat-all era, antiretroviral therapy (ART) interruptions contribute to an increasing proportion of HIV infections and deaths. Many strategies to improve retention on ART cost more than standard of care. In this study, we aimed to estimate the upper-bound costs at which such interventions should be adopted.

Publication details

The Lancet Global Health
#10
2022
PDF